title: Improved antimicrobial host defense in mice following poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose glucan treatment by a gender-dependent immune mechanism.
abstract: Clinical trials with biological modifiers targeting specific inflammatory mediators associated with severe sepsis have shown no or limited survival benefit. The approach taken in studies reported here was to limit the point source of intra-abdominal infection by potentiating innate immune function, thereby lessening the severity of sepsis and improving survival. Soluble beta-glucans, glucose polymers of the fungal cell wall, have been shown to stimulate innate immune host defense in animal and human studies when administered prior to an infectious challenge. We evaluated the effects of poly-(1,6)-β-d-glucopyranosyl-(1,3)-β-d-glucopyranose glucan (PGG glucan) on overall survival when administered intraperitoneally after the onset of polymicrobial infection by cecal ligation and puncture (CLP). Since gender-dependent differences in host immune response to infection have been reported, male and female mice were prospectively stratified for PGG glucan treatment. Outbred CD-1 mice were administered 10 mg/kg of body weight PGG glucan or the polysaccharide control, dextran, 1 h after CLP. Six hours after CLP, blood samples were obtained for cytokine measurements. Surprisingly, a gender-dependent effect on the response to PGG glucan was revealed. PGG glucan enhanced survival in female mice over a 10-day period, but survival in males was improved for only 24 h. In female mice, PGG glucan reduced interleukin-6 (IL-6) and IL-10 levels and reduced the bacterial burden in the liver. Ovariectomy abrogated the response to PGG glucan. Together, the translational potential of these findings is the indicated use of PGG glucan given locally, rather than intravenously, for improved source control during the management of sepsis. This therapy does not require prophylactic beta-glucan administration.
authors: Department of Surgery,, Division of Surgical Research, Rhode Island Hospital, Providence, RI 02903, USA.
authors: Courtni T
authors: CT
authors: Newsome
authors: Estefany
authors: E
authors: Flores
authors: Alfred
authors: A
authors: Ayala
authors: Stephen
authors: S
authors: Gregory
authors: Jonathan S
authors: JS
authors: Reichner
mesh_terms: D000818:Animals; D001424:Bacterial Infections / Q000276:immunology* / Q000401:mortality*; D058491:Bacterial Load; D005260:Female; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000276:immunology; D007274:Injections, Intraperitoneal; D016753:Interleukin-10 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008099:Liver / Q000382:microbiology; D008297:Male; D051379:Mice; D018805:Sepsis / Q000276:immunology* / Q000401:mortality*; D012737:Sex Factors; D016019:Survival Analysis; D013997:Time Factors; D047071:beta-Glucans / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D007155:Immunologic Factors; D015850:Interleukin-6; D047071:beta-Glucans; C069894:poly-1-6-glucopyranosyl-1-3-glucopyranose glucan; D016753:Interleukin-10